Office of the Secretary; Amended Notice of Meeting, 30449 [2018-13895]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 125 / Thursday, June 28, 2018 / Notices
amozie on DSK3GDR082PROD with NOTICES1
Intellectual Property
United States Provisional Patent
Application No. 61/040,005, filed March
27, 2008 and entitled ‘‘Human
Monoclonal Antibodies Specific for
Mesothelin’’ [HHS Reference No.
E–079–2008/0–US–01];
PCT Patent Application PCT/US2009/
038228, filed March 25, 2009 and
entitled ‘‘Human Monoclonal Antibody
Against Mesothelin’’ [HHS Reference
No. E–079–2008/0–PCT–02]; and US
Patent No. 8,357,783, filed September
22, 2010, Issued January 22, 2013 and
entitled ‘‘Human Anti-Mesothelin
Monoclonal Antibodies’’ [HHS
Reference No. E–079–2008/0–US–06].
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to: ‘‘The
development of a mesothelin chimeric
antigen receptor (CAR)-based
immunotherapy using autologous or
allogeneic T cells either transduced
with a retroviral vector (including
lentiviral vectors) or modified using a
gene-editing technology, wherein the
vector expresses a CAR comprising:
(1) Single antigen specificity for
binding to mesothelin, and
(2) at least (a) the complementary
determining region (CDR) sequences of
the anti-mesothelin antibody known as
m912, and (b) a T cell signaling domain;
for the prophylaxis and treatment of
mesothelin-expressing human cancers.’’
This technology discloses a
monoclonal antibody and methods of
using the antibody for the treatment of
mesothelin-expressing cancers,
including mesothelioma, lung cancer,
stomach/gastric cancer, ovarian cancer,
and pancreatic cancer. The specific
antibody covered by this technology is
designated as m912, which is a fully
human monoclonal antibody against
mesothelin.
Mesothelin is a cell surface antigen
that is preferentially expressed on
certain types of cancer. The m912
antibody selectively binds to the
mesothelin on the surface of cancer cells
and induces cell death of those cancer
cells while leaving healthy cells
unharmed. This selectivity may lead to
fewer side effects due to decreased nonspecific killing of cells.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
VerDate Sep<11>2014
17:08 Jun 27, 2018
Jkt 244001
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: June 21, 2018
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2018–13893 Filed 6–27–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Secretary; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Interagency Pain
Research Coordinating Committee, July
09, 2018, 02:00 p.m. to July 09, 2018,
04:00 p.m., National Institutes of Health,
Building 31, 31 Center Drive,
Conference Room 6, Bethesda, MD,
20892 which was published in the
Federal Register on May 18, 2018, 83
FR 23283.
The meeting notice is amended to
change the time of the meeting from 2–
4 p.m. to 4–6 p.m. Date has not changed.
The meeting is open to the public.
Dated: June 22, 2018.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–13895 Filed 6–27–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Notice of Meetings
Substance Abuse and Mental
Health Services Administration; Centers
AGENCY:
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
30449
for Disease Control and Prevention;
Department of Health and Human
Services.
ACTION: Notice of meetings.
Notice is hereby given of the
meetings on July 22–23, 2018, of the
Substance Abuse and Mental Health
Services Administration’s (SAMHSA)
Tribal Technical Advisory Committee
(TTAC); on July 23 and July 25, 2018,
of the Centers for Disease Control and
Prevention (CDC)/Agency for Toxic
Substances and Disease Registry
(ATSDR) Tribal Advisory Committee
(TAC); and on July 24, 2018, of the Joint
Tribal Advisory Committee (JTAC).
DATES:
SAMHSA TTAC
July 22, 2018, 1:00 p.m. to 5:00 p.m.
EDT (OPEN)
July 23, 2018, 9:00 a.m. to 5:00 p.m.
EDT (OPEN)
• CDC/ATSDR TAC
July 23, 2018, 8:00 a.m. to 6:00 p.m.
EDT (OPEN)
July 25, 2018, 8:00 a.m. to 12:00 p.m.
EDT (OPEN)
• JTAC
July 24, 2018, 1:00 p.m. to 5:00 p.m.
EDT, (OPEN)
ADDRESSES:
• SAMHSA TTAC
Marriott Wardman Park Hotel, 2660
Woodley Road NW, Washington,
DC 20008
• CDC/ATSDR TAC
HHS Headquarters, Hubert H.
Humphrey Building, 200
Independence Avenue SW,
Washington, DC 20201
• JTAC
HHS Headquarters, Hubert H.
Humphrey Building, 200
Independence Avenue SW,
Washington, DC 20201.
FOR FURTHER INFORMATION CONTACT:
TTAC and JTAC, Mirtha Beadle, MPA,
Director, Office of Tribal Affairs and
Policy, Substance Abuse and Mental
Health Services Administration, 5600
Fishers Lane, Rockville, Maryland
20857, Telephone: (240) 276–0641,
Email: otap@samhsa.hhs.gov.
CDC/ATSDR/TAC, Carmen Clelland,
PharmD, MPA, MPH, Associate
Director for Tribal Support, Office for
State, Tribal, Local and Territorial
Support, Centers for Disease Control
and Prevention, 4770 Buford
Highway, Mailstop E–70, Atlanta, GA
30341–3717, Telephone: (404) 498–
2205, Email: cclelland@cdc.gov.
SUPPLEMENTARY INFORMATION: Pursuant
to Presidential Executive Order 13175
signed on November 6, 2000 and the
Presidential Memorandum of September
23, 2004, SAMHSA established the
SUMMARY:
E:\FR\FM\28JNN1.SGM
28JNN1
]]>Agencies
[Federal Register Volume 83, Number 125 (Thursday, June 28, 2018)]
[Notices]
[Page 30449]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-13895]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of the Secretary; Amended Notice of Meeting
Notice is hereby given of a change in the meeting of the
Interagency Pain Research Coordinating Committee, July 09, 2018, 02:00
p.m. to July 09, 2018, 04:00 p.m., National Institutes of Health,
Building 31, 31 Center Drive, Conference Room 6, Bethesda, MD, 20892
which was published in the Federal Register on May 18, 2018, 83 FR
23283.
The meeting notice is amended to change the time of the meeting
from 2-4 p.m. to 4-6 p.m. Date has not changed. The meeting is open to
the public.
Dated: June 22, 2018.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-13895 Filed 6-27-18; 8:45 am]
BILLING CODE 4140-01-P
